Research Library — Page 50 | Reta Compare
3563 research articles. Page 50 of 143.
Articles
- 503A vs 503B Pharmacy Counts
- Tirzepatide Shortage Timeline: Key Dates
- Compounded GLP-1 Adverse Event Reports
- Bulks List Inclusion: 503A and 503B Status of GLP Peptides
- Outsourcing Facilities Association Litigation Outcomes
- State-Level Peptide Bills 2024–2025
- RFK Jr. and HHS Peptide Policy Statements
- BPC-157 and TB-500 Regulatory Status 2026
- FDA Inspection Activity at GLP-Compounding Pharmacies
- Compounded GLP-1 Patient Disruption Estimates
- Telehealth Platform Regulatory Settlements 2024–2026
- FDA Bulks List Process Statistics
- Eli Lilly Marketing Claim Disputes
- Compounded Semaglutide Volume Decline 2025–2026
- FDA Import Alerts Affecting Peptide API
- Compounded GLP-1 Insurance Coverage Reality
- Peptide Litigation Discovery Timelines 2026
- Compounded Retatrutide: A Different Legal Picture
- FDA Guidance Document Activity 2025–2026
- Compounding Quality Failure Rates
- Telehealth Platform Subscriber Churn 2025–2026
- Cross-Border Compounded GLP Activity
- Compounded Enforcement: Aggregate Costs to Industry
- Retatrutide: A New Era in Obesity Treatment with Multi-Receptor Agonists
- Exploring the Role of Retatrutide in Diabetes Management and Weight Loss